Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases
| Autor: | BLING Res Grp, Lamberg, Tea, Sipponen, Taina, Valtanen, Sanna, Eklund, Kari K., Mälkönen, Tarja, Aalto, Kristiina, Mikola, Katriina, Kolho, Kaija-Leena, Leinonen, Sanna, Isomäki, Pia, Mäkinen, Heidi, Vidqvist, Krista-Liisa, Kokko, Arto, Huilaja, Laura, Kyllönen, Minna, Keskitalo, Paula, Sard, Sirja, Vähäsalo, Paula, Koskela, Ritva, Kröger, Liisa, Lahtinen, Perttu, Haapala, Anna-Maija, Korkatti, Katja, Sokka-Isler, Tuulikki, Jokiranta, T. Sakari |
|---|---|
| Přispěvatelé: | HUSLAB, University of Helsinki, Clinicum, Gastroenterologian yksikkö, HUS Abdominal Center, HUS Inflammation Center, Department of Medicine, Reumatologian yksikkö, Department of Dermatology, Allergology and Venereology, HUS Children and Adolescents, Children's Hospital, HYKS erva, Päijät-Häme Welfare Consortium, Medicum, Tampere University, Clinical Medicine, Eye Centre, Department of Internal medicine, Department of Clinical Microbiology |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
rheumatoid arthritis
Immunology DISCONTINUATION 3121 Internal medicine THERAPY BIOLOGICS Rheumatic Diseases adalimumab Humans Immunology and Allergy DRUGS Treatment Failure Finland Retrospective Studies ulcerative colitis REGISTER Drug Substitution treatment interruption immunisation Crohn disease Infliximab RHEUMATOID-ARTHRITIS Case-Control Studies 3121 General medicine internal medicine and other clinical medicine ANTIBODIES juvenile idiopathic arthritis Tumor Necrosis Factor Inhibitors INFLAMMATORY-BOWEL-DISEASE |
| Popis: | Introduction: The prevalence of immune-mediated diseases has increased in the past decades and despite the use of biological treatments all patients do not achieve remission. The aim of this study was to characterise the reasons for short interruptions during treatment with two commonly used TNF-inhibitors infliximab and adalimumab and to analyse the possible effects of the interruptions on immunisation and switching the treatment. Material and methods: This case-control study was based on retrospective analyses of patient records and a questionnaire survey to clinicians. A total of 370 patients (194 immunised cases and 172 non-immunised controls, 4 excluded) were enrolled from eight hospitals around Finland. Eleven different diagnoses were represented, and the largest patient groups were those with inflammatory bowel or rheumatic diseases. Results: Treatment interruptions were associated with immunisation in patients using infliximab (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|